Zenas BioPharma
(NASDAQ) ZBIO
Zenas BioPharma Financials at a Glance
Market Cap
$1.75BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$425.15M
EPS (TTM)
-$9.10
P/E Ratio
-3.04
Dividend
$0.00
Beta (Volatility)
1.39 (Average)
Dividend
$0.00
Beta (Volatility)
1.39 (Average)
Price
$28.75
Volume
795,931.8
Open
$27.36
Price
$28.75
Volume
795,931.8
Open
$27.36
Previous Close
$28.77
Daily Range
$26.55 - $28.84
52-Week Range
$9.98 - $44.60
Estimated Earnings Date
Aug 11, 2026
Dividend
$0.00
Beta (Volatility)
1.39 (Average)
Price
$28.75
Volume
795,931.8
Open
$27.36
Previous Close
$28.77
Daily Range
$26.55 - $28.84
52-Week Range
$9.98 - $44.60
Estimated Earnings Date
Aug 11, 2026
ZBIO News
ZBIO: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Zenas BioPharma
Industry
Biotechnology
Sector
Health CareEmployees
167
CEO
Lonnie Moulder, Jr., MBA
Website
www.zenasbio.comHeadquarters
Waltham, MA 02451, US
ZBIO Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-167.71%
Return on Capital
-65.63%
Return on Assets
-56.86%
Earnings Yield
-32.89%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.75BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
63.13M
Volume
795.93K
Avg. Volume
709.78K
Financials (TTM)
Gross Profit
-$48.03M
Operating Income
-$423.08M
EBITDA
-$408.44M
Operating Cash Flow
-$210.48M
Capital Expenditure
-$2.00K
Free Cash Flow
-$210.48M
Cash & ST Invst.
$717.21M
Total Debt
$351.73M
Zenas BioPharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
-$6.00K
-100.1%
Gross Margin
0.00%
N/A
Market Cap
$1.75BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$10.46M
N/A
Employees
167
N/A
Net Income
-$80.99M
-141.2%
EBITDA
-$74.35M
-120.3%
Quarterly Fundamentals
Total Cash
$717.21M
+129.6%
Total Debt
$351.73M
+28612.6%
Accounts Receivable
$1.10M
N/A
Inventory
$0.00
N/A
Long Term Debt
$350.69M
+110528.4%
Short Term Debt
$1.04M
+14.2%
Return on Assets
-56.86%
N/A
Return on Invested Capital
-61.63%
N/A
Free Cash Flow
-$75.20M
-102.9%
Operating Cash Flow
-$75.20M
-103.0%